Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...
What is your sentiment on Nasdaq?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback